Literature DB >> 3805657

Comparison of ranitidine and sucralfate in the long-term treatment of duodenal ulcer.

G Masoero, F Rocchia, A Rossanino, M Marchetto, V Benitti, M De la Pierre.   

Abstract

We evaluated long-term treatment with either ranitidine (R) or sucralfate (S) in the prevention of duodenal ulcer recurrences. Fifty-nine patients with healed ulcers were randomly allocated to maintenance treatment with 150 mg R nightly or 2 g/day S. By using a life table analysis, the calculated probable remission rates at 4, 8, and 12 months were 90, 85, and 53% with R, respectively, and 62, 62, and 53% with S, respectively. These differences were not significant at any interval. In both groups ulcer relapse was independent of sex, smoking habit, and alcohol and coffee consumption, whereas a history longer than 5 years was significantly related to a higher probability of recurrence. No relevant clinical or biochemical side effects were encountered with either drug, but compliance rate was higher in the R group. R and S are equally effective in preventing duodenal ulcer relapse over a 1-year period of maintenance treatment, although R proved to be more effective in preventing early relapse.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3805657     DOI: 10.1097/00004836-198612000-00006

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  3 in total

Review 1.  Long term treatment of duodenal ulcer. A review of management options.

Authors:  G Bianchi Porro; F Parente
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

Review 2.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

3.  Two year maintenance treatment of duodenal ulcer disease with ranitidine 150 mg: a prospective multicentre randomised study. GEMUD (Groupe d'Etude de la Maladie Ulcéreuse Duodénale).

Authors:  P Ruszniewski; A Slama; M Pappo; M Mignon
Journal:  Gut       Date:  1993-12       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.